2024/09/24
TaiMed is invited to participate in institutional investor conference hosted by President Securities to share corporate financial information and business outlook
2024/08/30
TaiMed Biologics Announces Last Patient Completed Dosing in Phase 2a Study of Long-Acting TMB-365 and TMB-380 Combination Therapy for HIV Therapy
2024/08/08
TaiMed Biologics Achieves Positive Cash Flow for Two Consecutive Quarters, Significant Improvement in Operating Results Compared to Last Year
2024/08/07
TaiMed Announces its Marketing Partner WUZHOU Submitted Trogarzo Biological License Application (BLA) to the Hong kong and Macau Drug Administration Agencies
2024/07/23
TaiMed Biologics at BIO Asia-Taiwan 2024 (Business updated)
2024/07/19
The Company received patent approval from the US Patent and Trademark Office for improving the pharmacokinetic performance of TMB-365 using histidine modification technology
2024/07/10
TaiMed Biologics Showcases Innovative HIV Therapies at BioAsia 2024
2024/06/13
Taimed Biologics' CEO Featured in The Japan Times
2024/05/28
2024 Shareholder Meeting Video Recording
2024/05/28
TaiMed Biologics shared several exciting positive developments at its 2024 shareholders' meeting
2024/05/27
TaiMed to Showcase Innovative HIV Therapies at BIO 2024
2024/05/20
Taimed Biologics And Orient EuroPharma Signs Trogarzo® Commercial License Agreement In Taiwan
2024/05/13
TaiMed's operations have improved significantly in the first quarter of 2024, approaching the breakeven at profit and loss.
2024/05/10
TaiMed Announces Enrollment of the last Patient in Phase 2a Study of the Long-Acting TMB-365/TMB-380 mAb Combination for the Bi-monthly Injection Maintenance HIV Therapy
2024/04/09
TaiMed is invited to participate in institutional investor conference hosted by MasterLink Securities to share corporate financial information and business outlook